An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

Anti-Cancer Drugs

Volumn 8, Issue 7, 1997, Pages 657-661

  Kudelka, Andrzej P ^a   Winn, Rodger ^a   Edwards, Creighton L ^a   Downey, G ^b   Greenberg, Harvey ^c   Dakhil, S R ^d   Freedman, Ralph S ^a   LoCoco, Salvatore ^e   Umbreit, J ^f   Delmore, James E ^g   Arbuck, Susan ^h   Loyer, Evelyne ^a   Gacrama, Patsy ^a   Fueger, Rebecca ^a   Kavanagh, John J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM   (United States)

^c Providence Memorial Hospital   (United States)

^d WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^e Texas Cancer Care   (United States)

^f UNIVERSITY OF SOUTH ALABAMA   (United States)

^g Associates in Women's Health   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cervix cancer; Granulocyte colony stimulating factor; Paclitaxel

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MYALGIA; NAUSEA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PATIENT SELECTION; RECURRENCE; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 9844223395     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199708000-00002     Document Type: Article

References (32)

1. Devasa SS, Silverman DT, Young JL, et al. Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst 1987; 79: 701 70.
2. Parkin DM, Muir CS, Whelan SL, et al. (eds). Cancer incidence in five continents, vol VI. Lyon: International Agency for Research on Cancer 1992.
3. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 8-30.
4. Thigpen T, Vance RB, Khansur T. Carcinoma of the uterine cervix: current status and future directions. Semin Oncol 1994; 21 (suppl 2): 43-54.
5. Bonomi P, Blessing JA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985; 3: 1079-85.
6. Coleman RE, Harper PG, Gallagher C, et al. A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 1986; 18: 280-3.
7. Takeuchi S, Noda K, Yakushiji M, Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma (CC). Proc Am Soc Clin Oncol 1992; 11: A708.
8. Kavanagh JJ, Kudelka AP, Edwards CE, et al. CPT-11 (Irinotecan): phase II study in refractory squamous cell carcinoma of the cervix. Proc Am Ass Cancer Res 1994; 35: A1397.
9. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II trial of CPT-11 in refractory cervical cancer. J Clin Oncol 1997; 15: 625-31.
10. Goedhals L, Bezwoda WR, Smith BL, et al. Phase II study of gemcitabine in advanced cervical cancer. Recent Clin Adv Gemzar 1996; 3: 52-3.
11. Wall ME, Wani MC. Paclitaxel: from discovery to clinic. In: George GI, Chen TT, Ojima I, Vyas DM, eds. ACS symposium-in-print: taxane anticancer agents: basic-science and current status. Washington, DC: ACS 1995; 583: 18-30.
12. Schiff PB, Fant J, Horowitz S. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 22: 665-7.
13. Pazdur R, Kudelka AP, Kavanagh JJ, et al. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993; 19: 351-86.
14. Holmes FA, Kudelka AP, Kavanagh JJ, et al. Current status of clinical trials with paclitaxel and docetaxel. In: George CI, Chen TT, Ojima I, Vyas DM, eds. ACS symposium-inprint: taxane anticancer agents: basic science and current status. Washington, DC: ACS 1995; 583: 31-57.
15. Sarosy G, Kohn E, Stone DA, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer, J Clin Oncol 1992; 10: 1165 70.
16. Sarosy G, Kohn E, Link C, et al. Taxol dose intensification (DI) in patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol 1992; 11: 716.
17. Kavanagh JJ, Kudelka AP, Edwards CL, et al. A randomized cross-over trial of parenteral hydroxyurea vs high-dose taxol in cisplatin/carboplatin-resistant epithelial ovarian cancer. Proc Am Soc Clin Oncol 1993; 13: 259.
18. Forastiere AA. Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck (review). Semin Oncol 1993; 20: 56-60.
19. Thornton D, Singh K, Putz B, et al. A phase II trial of taxol in squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1994; 13: abstr 933.
20. Ajani JA, Ilson DH, Daugherty K, et al. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86: 1086-91.
21. Kudelka AP, Winn R, Edwards CL, et al. Report of the activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Clin Cancer Res 1996; 2: 1285- 8.
22. 2 administered intravenously over three hours every 21 days with G-CSF support. Proc Am Soc Clin Oncol 1997; 16: abstr 1327.
23. Gehan EA. Number of patients required in a new drug trial. J Chron Dis 1961; 13: 346-53.
24. Lopez A, Kudelka AP, Edwards CL, et al. Carcinoma of the uterine cervix. In: Pazdur R, ed. Medical oncology: a comprehensive review. Huntington: PRR 1995; 22: 393- 405.
25. McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996; 14: 792- 5.
26. Bicher A, Kohn E, Sarosy G, et al. The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor. Anti-Cancer Drugs 1993; 4: 141-8.
27. Diamandidou E, Kavanagh JJ, Kudelka AP, et al. Ovarian cancer. In Pazdur R, ed. Medical oncology: a comprehensive review. Huntington: PRR 1995; 22: 359-75.
28. Ozols RF. Current status of chemotherapy for ovarian cancer. Semin Oncol 1995; 22: 61-6.
29. Costa MA, Rocha JCC, Araujo CM, et al. Paclitaxel and cisplatin as primary medical treatment in locally advanced cervical cancer. Proc Am Soc Clin Oncol 1997; 16: abstr 1311.
30. Rose PG, Blessing JA, Gershenson DM. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 1997; 16: abstr 1291.
31. Tishler RB, Schiff PB, Gerard CR, et al. A novel radiation sensitizer. Int J Radiat Oncol 1992; 22: 613-7.
32. Colombo N, Landoni F, Pellegrino A, et al. Phase II study of cisplatin, ifosfamide and paclitaxel as neoadjuvant chemotherapy in patients with locally advanced cervical carcinoma. Proc Am Soc Clin Oncol 1997; 16: abstr 1309.